MIDF Research said the group has increased its profitability in the last few months as demand for pharmaceutical products continued to rise well into the second half of the year.皇冠开户平台（www.hg9988.vip）是皇冠官方开户平台，开放皇冠信用网代理申请、信用网会员开户，线上投注的官方平台。
KUALA LUMPUR: Pharmaniaga Bhd is expected to post positive earnings in financial years 2022 (FY22) and FY23 as demand for pharmaceutical products continues to increase.
In a note, MIDF Research said the group has increased its profitability in the last few months as demand for pharmaceutical products continued to rise well into the second half of the year.
“Despite having no problems with raw materials, Pharmaniaga has stated that the high demand has caused manufacturing to go beyond 100% capacity, and paracetamol production had increased to more than twice the normal capacity.
“Liquid drugs are also facing a demand and supply imbalance, as such, Pharmaniaga’s Indonesian plants have been requested to deliver the syrups,” the research house pointed out.,
,telegram中文群组索引（www.tel8.vip）是一个Telegram群组分享平台，telegram中文群组索引包括telegram中文群组索引、telegram群组索引、Telegram群组导航、新加坡telegram群组、telegram中文群组、telegram群组（其他）、Telegram 美国 群组、telegram群组爬虫、电报群 科学上网、小飞机 怎么 加 群、tg群等内容。telegram中文群组索引为广大电报用户提供各种电报群组/电报频道/电报机器人导航服务。
MIDF Research also added that Pharmaniaga’s logistics segment will be renewing its concession agreement with the government in the fourth quarter of 2022, assuring a steady order of drugs for public hospitals in the near term.
Additionally, the group’s efforts to push its brands to become household names could reset the public sentiment that only certain brands of drugs would give out the same effect, hence boosting its future income.
“We are also optimistic on its vending machine venture which is part of the pharmaceutical sector’s solution to accessibility and digital healthcare,” it said. — Bernama